

# Myocardial Infarction Drug-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/ME715B5C474MEN.html>

Date: March 2018

Pages: 152

Price: US\$ 3,480.00 (Single User License)

ID: ME715B5C474MEN

## Abstracts

### Report Summary

Myocardial Infarction Drug-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Myocardial Infarction Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Myocardial Infarction Drug 2013-2017, and development forecast 2018-2023

Main market players of Myocardial Infarction Drug in United States, with company and product introduction, position in the Myocardial Infarction Drug market

Market status and development trend of Myocardial Infarction Drug by types and applications

Cost and profit status of Myocardial Infarction Drug, and marketing status

Market growth drivers and challenges

The report segments the United States Myocardial Infarction Drug market as:

United States Myocardial Infarction Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

## Southwest

United States Myocardial Infarction Drug Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

JVS-200  
KR-33028  
AMRS-001  
ANG-4011  
Balixafortide  
CAP-1002  
Cenderitide  
Others

United States Myocardial Infarction Drug Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and  
Market Analysis)

Research Center  
Hospital  
Clinic

United States Myocardial Infarction Drug Market: Players Segment Analysis (Company  
and Product introduction, Myocardial Infarction Drug Sales Volume, Revenue, Price and  
Gross Margin):

BioCardia, Inc.  
Biscayne Pharmaceuticals, Inc.  
Capricor Therapeutics, Inc.  
CellProthera  
Celyad SA  
Compugen Ltd.  
CSL Limited  
Cynata Therapeutics Limited  
FibroGen, Inc.  
Hemostemix Ltd  
Human Stem Cells Institute  
HUYA Bioscience International, LLC  
Immune Pharmaceuticals Inc.  
Juventas Therapeutics, Inc.  
Laboratoires Pierre Fabre SA  
Lee's Pharmaceutical Holdings Limited

LegoChem Biosciences, Inc

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF MYOCARDIAL INFARCTION DRUG**

- 1.1 Definition of Myocardial Infarction Drug in This Report
- 1.2 Commercial Types of Myocardial Infarction Drug
  - 1.2.1 JVS-200
  - 1.2.2 KR-33028
  - 1.2.3 AMRS-001
  - 1.2.4 ANG-4011
  - 1.2.5 Balixafortide
  - 1.2.6 CAP-1002
  - 1.2.7 Cenderitide
  - 1.2.8 Others
- 1.3 Downstream Application of Myocardial Infarction Drug
  - 1.3.1 Research Center
  - 1.3.2 Hospital
  - 1.3.3 Clinic
- 1.4 Development History of Myocardial Infarction Drug
- 1.5 Market Status and Trend of Myocardial Infarction Drug 2013-2023
  - 1.5.1 United States Myocardial Infarction Drug Market Status and Trend 2013-2023
  - 1.5.2 Regional Myocardial Infarction Drug Market Status and Trend 2013-2023

### **CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Myocardial Infarction Drug in United States 2013-2017
- 2.2 Consumption Market of Myocardial Infarction Drug in United States by Regions
  - 2.2.1 Consumption Volume of Myocardial Infarction Drug in United States by Regions
  - 2.2.2 Revenue of Myocardial Infarction Drug in United States by Regions
- 2.3 Market Analysis of Myocardial Infarction Drug in United States by Regions
  - 2.3.1 Market Analysis of Myocardial Infarction Drug in New England 2013-2017
  - 2.3.2 Market Analysis of Myocardial Infarction Drug in The Middle Atlantic 2013-2017
  - 2.3.3 Market Analysis of Myocardial Infarction Drug in The Midwest 2013-2017
  - 2.3.4 Market Analysis of Myocardial Infarction Drug in The West 2013-2017
  - 2.3.5 Market Analysis of Myocardial Infarction Drug in The South 2013-2017
  - 2.3.6 Market Analysis of Myocardial Infarction Drug in Southwest 2013-2017
- 2.4 Market Development Forecast of Myocardial Infarction Drug in United States 2018-2023
  - 2.4.1 Market Development Forecast of Myocardial Infarction Drug in United States

2018-2023

2.4.2 Market Development Forecast of Myocardial Infarction Drug by Regions

2018-2023

## **CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Myocardial Infarction Drug in United States by Types

3.1.2 Revenue of Myocardial Infarction Drug in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Myocardial Infarction Drug in United States by Types

## **CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Myocardial Infarction Drug in United States by Downstream Industry

4.2 Demand Volume of Myocardial Infarction Drug by Downstream Industry in Major Countries

4.2.1 Demand Volume of Myocardial Infarction Drug by Downstream Industry in New England

4.2.2 Demand Volume of Myocardial Infarction Drug by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of Myocardial Infarction Drug by Downstream Industry in The Midwest

4.2.4 Demand Volume of Myocardial Infarction Drug by Downstream Industry in The West

4.2.5 Demand Volume of Myocardial Infarction Drug by Downstream Industry in The South

4.2.6 Demand Volume of Myocardial Infarction Drug by Downstream Industry in Southwest

4.3 Market Forecast of Myocardial Infarction Drug in United States by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF MYOCARDIAL INFARCTION DRUG**

- 5.1 United States Economy Situation and Trend Overview
- 5.2 Myocardial Infarction Drug Downstream Industry Situation and Trend Overview

## **CHAPTER 6 MYOCARDIAL INFARCTION DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES**

- 6.1 Sales Volume of Myocardial Infarction Drug in United States by Major Players
- 6.2 Revenue of Myocardial Infarction Drug in United States by Major Players
- 6.3 Basic Information of Myocardial Infarction Drug by Major Players
  - 6.3.1 Headquarters Location and Established Time of Myocardial Infarction Drug Major Players
  - 6.3.2 Employees and Revenue Level of Myocardial Infarction Drug Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 MYOCARDIAL INFARCTION DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 BioCardia, Inc.
  - 7.1.1 Company profile
  - 7.1.2 Representative Myocardial Infarction Drug Product
  - 7.1.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of BioCardia, Inc.
- 7.2 Biscayne Pharmaceuticals, Inc.
  - 7.2.1 Company profile
  - 7.2.2 Representative Myocardial Infarction Drug Product
  - 7.2.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of Biscayne Pharmaceuticals, Inc.
- 7.3 Capricor Therapeutics, Inc.
  - 7.3.1 Company profile
  - 7.3.2 Representative Myocardial Infarction Drug Product
  - 7.3.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of Capricor Therapeutics, Inc.

#### 7.4 CellProthera

##### 7.4.1 Company profile

##### 7.4.2 Representative Myocardial Infarction Drug Product

##### 7.4.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of CellProthera

#### 7.5 Celyad SA

##### 7.5.1 Company profile

##### 7.5.2 Representative Myocardial Infarction Drug Product

##### 7.5.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of Celyad SA

#### 7.6 Compugen Ltd.

##### 7.6.1 Company profile

##### 7.6.2 Representative Myocardial Infarction Drug Product

##### 7.6.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of Compugen Ltd.

#### 7.7 CSL Limited

##### 7.7.1 Company profile

##### 7.7.2 Representative Myocardial Infarction Drug Product

##### 7.7.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of CSL Limited

#### 7.8 Cynata Therapeutics Limited

##### 7.8.1 Company profile

##### 7.8.2 Representative Myocardial Infarction Drug Product

##### 7.8.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of Cynata Therapeutics Limited

#### 7.9 FibroGen, Inc.

##### 7.9.1 Company profile

##### 7.9.2 Representative Myocardial Infarction Drug Product

##### 7.9.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of FibroGen, Inc.

#### 7.10 Hemostemix Ltd

##### 7.10.1 Company profile

##### 7.10.2 Representative Myocardial Infarction Drug Product

##### 7.10.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of Hemostemix Ltd

#### 7.11 Human Stem Cells Institute

##### 7.11.1 Company profile

##### 7.11.2 Representative Myocardial Infarction Drug Product

##### 7.11.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of Human

Stem Cells Institute

7.12 HUYA Bioscience International, LLC

7.12.1 Company profile

7.12.2 Representative Myocardial Infarction Drug Product

7.12.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of HUYA

Bioscience International, LLC

7.13 Immune Pharmaceuticals Inc.

7.13.1 Company profile

7.13.2 Representative Myocardial Infarction Drug Product

7.13.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of Immune

Pharmaceuticals Inc.

7.14 Juventas Therapeutics, Inc.

7.14.1 Company profile

7.14.2 Representative Myocardial Infarction Drug Product

7.14.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of

Juventas Therapeutics, Inc.

7.15 Laboratoires Pierre Fabre SA

7.15.1 Company profile

7.15.2 Representative Myocardial Infarction Drug Product

7.15.3 Myocardial Infarction Drug Sales, Revenue, Price and Gross Margin of

Laboratoires Pierre Fabre SA

7.16 Lee's Pharmaceutical Holdings Limited

7.17 LegoChem Biosciences, Inc

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MYOCARDIAL INFARCTION DRUG**

8.1 Industry Chain of Myocardial Infarction Drug

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF MYOCARDIAL INFARCTION DRUG**

9.1 Cost Structure Analysis of Myocardial Infarction Drug

9.2 Raw Materials Cost Analysis of Myocardial Infarction Drug

9.3 Labor Cost Analysis of Myocardial Infarction Drug

9.4 Manufacturing Expenses Analysis of Myocardial Infarction Drug



## **CHAPTER 10 MARKETING STATUS ANALYSIS OF MYOCARDIAL INFARCTION DRUG**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Myocardial Infarction Drug-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/ME715B5C474MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ME715B5C474MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970